6-[5-(aminomethyl)-2-oxo-oxazolidin-3-yl]-3H-benzoxazol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 6-[5-(aminomethyl)-2-oxo-oxazolidin-3-yl]-3H-benzoxazol-2-one
• 英文别名: 6-[5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one
• 化学式: C₁₁H₁₁N₃O₄
• 分子量: 249.226
• InChiKey: KCUZHKGHMLOSHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  93.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
  申请人：——

  公开号：US20030004212A1

  公开（公告）日：2003-01-02

  Described are cyclohexylamine derivatives of Formula I 1 and pharmaceutically acceptable salts thereof, wherein R 1 , g, *, R, V, B, E, Y, G, H, X 1 , and d are as defined in the description. The compounds of Formulas I, VI, and VIa are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, trauma, hypoglycemia, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence.

  本文描述了公式I1的环己胺衍生物及其药学上可接受的盐，其中R1、g、*、R、V、B、E、Y、G、H、X1和d的定义如描述中所示。公式I、VI和VIa的化合物是NMDA受体通道复合物的拮抗剂，可用于治疗脑血管疾病，例如中风、脑缺血、创伤、低血糖、焦虑、偏头痛、惊厥、帕金森病、氨基糖苷类抗生素引起的听力损失、精神病、青光眼、CMV视网膜炎、阿片类药物耐受或戒断、慢性疼痛或尿失禁。
• Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1251128A1

  公开（公告）日：2002-10-23

  Described are cyclohexylamine derivatives of Formula I Formula VI and Formula VIa and pharmaceutically acceptable salts thereof, wherein R1, g, *, R, V, B, E, Y, G, H, X1, and d are as defined in the description. The compounds of Formulas I and VI are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, trauma, hypoglycemia, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence.

  所述的是式 I 的环己胺衍生物 式 VI 和式 VIa 及其药学上可接受的盐类，其中 R1、g、*、R、V、B、E、Y、G、H、X1 和 d 如说明中所定义。式 I 和 VI 的化合物是 NMDA 受体通道复合物的拮抗剂，可用于治疗脑血管疾病，例如中风、脑缺血、创伤、低血糖、焦虑、偏头痛、抽搐、帕金森病、氨基糖苷类抗生素引起的听力损失、精神病、青光眼、CMV 视网膜炎、阿片类药物耐受或戒断、慢性疼痛或尿失禁。
• Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
  申请人：LegoChem Biosciences, Inc.

  公开号：US10961242B2

  公开（公告）日：2021-03-30

  The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

  本发明涉及作为自体毒素抑制剂的新型化合物，用于治疗和预防由自体毒素激活或溶血磷脂酸浓度升高引起的病症或紊乱，以及含有本发明的药物组合物。 本发明的新型化合物是自体毒素抑制剂，通过抑制溶血磷脂酸的产生，可用于治疗或预防心血管疾病、癌症、代谢紊乱、肾脏疾病、肝脏疾病、炎症性疾病、神经系统疾病、呼吸系统疾病、纤维化疾病、眼部疾病、胆汁淤积性和其他形式的慢性瘙痒症，或急性或慢性器官移植排斥反应。
• NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Legochem Bioscience Ltd.

  公开号：EP3442973A1

  公开（公告）日：2019-02-20
• US6828341B2
  申请人：——

  公开号：US6828341B2

  公开（公告）日：2004-12-07